ArticleIJID regions2026
Under-ascertainment of medically attended tick-borne encephalitis virus infections by tick-borne encephalitis surveillance in selected areas of Austria, Denmark, Finland, Germany, Latvia, Sweden, and Switzerland.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Antibodies against tick-borne encephalitis (TBE) virus (TBEV) nonstructural protein 1 (NS1) immunoglobulin G are elevated in TBEV-infected individuals, but not in TBE vaccinated individuals, enabling estimation of TBEV infection prevalence in countries where TBE vaccines are used. Methods: We used data from NS1 seroprevalence studies to estimate the incidence of medically attended TBEV infections and then compared this incidence with the incidence of surveillance-reported TBE cases to estimate the under-ascertainment multiplier for medically attended TBEV infections identified by surveillance. Results: The prevalence of NS1 antibodies ranged from 0.1% to 7.0% in the identified nine seroprevalence studies. Medically attended TBEV incidence in areas where seroprevalence specimens were collected ranged from 0.5/100,000 population per year in Denmark to 21.5/100,000 population per year in Latvia. The under-ascertainment multiplier was 0.9 in Finland, 2.2 in Latvia, 2.5 in Switzerland, 3.4 in Sweden, 3.6 in Austria(Northern), 3.8 in Germany (Bavaria), 5.0 in Austria (Western), 5.0 in Denmark, and 6.0 in Germany-Baden/Wuerttemberg. Conclusion: Despite assumptions necessitated by data gaps, the results of this analysis indicate that more individuals are infected with TBEV and seek medical care than are ascertained by TBE surveillance. Given the increasing public health threat posed by TBE in Europe, further efforts are needed to improve TBE awareness and increase TBE vaccination among persons at increased risk of TBEV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.